[EN] ROR-GAMMA INHIBITORS<br/>[FR] INHIBITEURS DE ROR-GAMMA
申请人:GLAXOSMITHKLINE IP DEV LTD
公开号:WO2019063748A1
公开(公告)日:2019-04-04
The present invention relates to compounds of formula I and pharmaceutical compositions comprising compounds of formula I. Compounds of Formula I are useful in treatment of inflammatory, metabolic or autoimmune diseases which are mediated by RORy.
[EN] META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS<br/>[FR] DERIVES DE LA META-GUANIDINE, DE L'UREE, DE LA THIO-UREE OU DE L'ACIDE AMINOBENZOIQUE AZACYCLIQUE UTILISES COMME ANTAGONISTES DE L'INTEGRINE
申请人:G.D. SEARLE & CO.
公开号:WO1997008145A1
公开(公告)日:1997-03-06
(EN) The present invention relates to a class of compounds represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein A is (a) or (b) or (c) or (d) pharmaceutical compositions thereof and methods of using such compounds and compositions as $g(a)v$g(b)3 integrin antagonists.(FR) L'invention concerne une classe de composés représentés par la formule I et leurs sels acceptables sur le plan pharmaceutique. Dans cette formule, A est (a) ou (b) ou (c) ou (d). L'invention concerne également des préparations pharmaceutiques contenant ces composés, ainsi que des procédés d'utilisation de ces composés et de ces préparations comme antagonistes de l'intégrine $g(a)v$g(b)3.
META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
申请人:G.D. SEARLE & CO.
公开号:EP0850221B1
公开(公告)日:2001-07-18
US6028223A
申请人:——
公开号:US6028223A
公开(公告)日:2000-02-22
Expedient Syntheses of Sulfonylhydantoins and Two Six-Membered Analogues
作者:Andrew D. Campbell、Alan M. Birch
DOI:10.1055/s-2005-863735
日期:——
A range of α-amino esters can be turned into sulfonylhydantoins 2 in a single, atom-economic step using sulfamide and DBU. This procedure obviates the need for a three- or four-step sequence utilised by traditional procedures. Two new six-membered analogues 3 and 4 have also been prepared utilising novel synthetic protocols.